J.Jpn. Surg. Soc.
ISSN 1880-1129

[Abstract] [Full Text HTML] [Full Text PDF] （in Japanese / 1541KB） [PDF: Members Only][Back to Search Results]

J.Jpn. Surg. Soc.. 122(5): 476-483, 2021

Feature topic

TREATMENT STRATEGY OF REDO AORTIC VALVE REPLACEMENT AFTER THE APPROVAL OF TRANSCATHETER AORTIC VALVE-IN-SURGICAL AORTIC VALVE

Department of Minimally Invasive Cardiovascular Medicine, Osaka University, Suita, Japan

Toru Kuratani

Transcatheter aortic valve-in-surgical aortic valve (TAV-in-SAV) is now covered by insurance for reoperation after aortic valve replacement due to valve degradation. The early results of TAV-in-SAV are better than redo surgical aortic valve replacement (SAVR) due to its minimally invasive nature. However, the results of TAV-in-SAV for small surgical valves remain dependent on pressure gradient, and the current indications for TAV-in-SAV are limited. To implement such a strategy, it is imperative that surgeons have the skills and knowledge to perform both techniques (redo SAVR and TAV-in-SAV). We sincerely hope that surgeons will perform minimally invasive surgery for structural heart disease.

Go to Page Top

To read the PDF file you will need Adobe Reader installed on your computer.